Evidence map›Paper›PMID 32901343›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2020

Targeting X chromosome-linked inhibitor of apoptosis protein in mucoepidermoid carcinoma of the head and neck: A novel therapeutic strategy using nitidine chloride.

Hye-Jeong Kwon, Kyungsil Yoon, Ji-Youn Jung, Mi Heon Ryu, Sung-Hyun Kim, Eun-Seon Yoo, So-Young Choi, In-Hyoung Yang, Seong Doo Hong, Ji-Ae Shin and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Hye-Jeong KwonDepartment of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea.
Kyungsil YoonComparative Biomedicine Research Branch, Division of Translational Science, National Cancer Center, Goyang, 10408, Republic of Korea.
Ji-Youn JungDepartment of Companion and Laboratory Animal Science, Kongju National University, Yesan, 32439, Republic of Korea.
Mi Heon RyuDepartment of Oral Pathology, School of Dentistry, Yangsan Campus of Pusan National University, Yangsan, 50612, Republic of Korea.
Sung-Hyun KimDepartment of Companion and Laboratory Animal Science, Kongju National University, Yesan, 32439, Republic of Korea.
Eun-Seon YooDepartment of Companion and Laboratory Animal Science, Kongju National University, Yesan, 32439, Republic of Korea.
So-Young ChoiDepartment of Oral and Maxillofacial Surgery, School of Dentistry, Kyungpook National University, Daegu, 41940, Republic of Korea.
In-Hyoung YangDepartment of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea.
Seong Doo HongDepartment of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea.
Ji-Ae ShinDepartment of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. sky21sm@snu.ac.kr.ORCID 0000-0002-5407-2611
Sung-Dae ChoDepartment of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. efiwdsc@snu.ac.kr.
Seoul National University · KRKongju National University · KRKyungpook National University · KRNational Cancer Center · KRPusan National University Yangsan Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitidine chloride (NC) was recently reported to exhibit a wide range of pharmacological properties for several diseases, including cancer. Here we report for the first time that NC is a potential therapeutic agent for mucoepidermoid carcinoma (MEC) occurring in the head and neck because it suppresses X chromosome-linked inhibitor of apoptosis protein (XIAP) in human MEC in vitro and in vivo. The antitumor effects of NC were evaluated by trypan blue exclusion assay, western blotting, live/dead assay, 4',6-diamidino-2-phenylindole (DAPI) staining, human apoptosis antibody array, immunofluorescence staining, immunohistochemistry, small interfering RNA assay, transient transfection of XIAP overexpression vector, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, and histopathological examination of organs. NC inhibited cell viability and induced caspase-dependent apoptosis in vitro. A human apoptosis antibody array assay showed that XIAP is suppressed by NC treatment. XIAP was overexpressed in oral squamous cell carcinoma (OSCC) tissues that arose from the head and neck, and high XIAP expression was correlated with poor prognosis in OSCC patients. XIAP depletion significantly increased apoptosis, and ectopic XIAP overexpression attenuated the apoptosis induced by NC treatment. NC suppressed tumor growth in vivo at a dosage of 5 mg/kg/day. The number of TUNEL-positive cells increased and the protein expression of XIAP was consistently downregulated in NC-treated tumor tissues. In addition, NC caused no histopathological changes in the liver or kidney. These findings provide new insights into the mechanism of action underlying the anticancer effects of NC and demonstrate that NC is a promising therapeutic agent for the treatment of human MEC of the head and neck. KEY MESSAGES: • Nitidine chloride induces caspase-dependent apoptosis in MEC of the head and neck. • High XIAP expression correlates with poor prognosis of OSCC patients. • Nitidine chloride suppresses tumor growth in vivo without any systemic toxicities. • Targeting XIAP is a novel chemotherapeutic strategy for MEC of the head and neck.

Indexed as

Biomarkers, TumorMolecular Targeted TherapyAntineoplastic AgentsApoptosisBenzophenanthridinesCarcinoma, MucoepidermoidCell Line, TumorCells, CulturedFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansImmunohistochemistryX-Linked Inhibitor of Apoptosis ProteinAntineoplastic AgentsBenzophenanthridinesBiomarkers, TumornitidineXIAP protein, humanX-Linked Inhibitor of Apoptosis ProteinApoptosisMucoepidermoid carcinoma of salivary glandNitidine chlorideX chromosome-linked inhibitor of apoptosis protein

Identifiers

PMID32901343
OpenAlexW3083953461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.